Question

Difficulty: HardSubstance-Related and Addictive Disorders

During a routine follow-up at a community health clinic, a 2929-year-old male construction worker describes experiencing severe restlessness, diffuse muscle aches, abdominal cramping, and insomnia over the previous 3636 hours. The patient discloses that he had been illicitly purchasing oxycodone to self-medicate for chronic lower back pain. However, he abruptly discontinued its use 22 days ago to 'get clean.' He is highly motivated to remain abstinent and emphatically declines any opioid-based substitution therapy, emphasizing his desire for a non-addictive treatment option. Vital signs reveal a temperature of 37.6∘C37.6^\circ\text{C} (99.7∘F99.7^\circ\text{F}), blood pressure of 156/98 mm Hg156/98\text{ mm Hg}, heart rate of 118 /min118\text{ /min}, and respiratory rate of 18 /min18\text{ /min}. Physical examination demonstrates an anxious, diaphoretic patient with prominent piloerection, frequent yawning, and mydriasis. To specifically target this patient's acute autonomic hyperarousal, the physician prescribes a non-opioid medication. Which of the following neuropharmacological mechanisms best describes the action of the most appropriate drug for this indication?

  1. A
    Positive allosteric modulation of GABA-A receptors
  2. B
    Inhibition of presynaptic serotonin reuptake
  3. Stimulation of central alpha-2 adrenergic receptorsAnswer
  4. D
    Antagonism of central dopamine D2 receptors
  5. E
    Blockade of peripheral beta-1 adrenergic receptors

Answer

Stimulation of central alpha-2 adrenergic receptors
This patient is experiencing acute opioid withdrawal, characterized by prominent sympathetic hyperarousal (tachycardia, hypertension, mydriasis, diaphoresis), piloerection, yawning, and gastrointestinal distress following the abrupt cessation of oxycodone. The standard of care for opioid withdrawal typically involves opioid agonist or partial agonist substitution (e.g., methadone, buprenorphine). However, because this patient explicitly refuses opioid-based therapies, non-opioid symptomatic management is indicated. The most appropriate pharmacologic intervention to mitigate the central autonomic hyperactivity in this setting is an alpha-2 adrenergic agonist, such as clonidine or lofexidine. These agents stimulate central alpha-2 receptors in the locus coeruleus, which effectively decreases sympathetic outflow and alleviates symptoms like tachycardia, hypertension, and diaphoresis.

Step-by-Step Solution

1
Analyze the patient's clinical presentation and vital signs.
The patient exhibits autonomic hyperactivity (tachycardia, hypertension, diaphoresis, mydriasis), piloerection, yawning, and gastrointestinal distress 3636 hours after discontinuing oxycodone.
To establish the diagnosis of acute opioid withdrawal.
2
Identify the patient's specific treatment preferences and constraints.
The patient explicitly refuses opioid-based substitution therapy (e.g., methadone, buprenorphine).
To determine that a non-opioid symptomatic management strategy is required.
3
Determine the most appropriate non-opioid medication to manage the central sympathetic hyperarousal.
Clonidine or lofexidine is indicated to suppress the central autonomic overdrive.
These agents target the locus coeruleus to relieve acute withdrawal symptoms.
4
Identify the neuropharmacological mechanism of the selected medication.
These medications act via stimulation of central alpha-2 adrenergic receptors.
To answer the specific question asked in the prompt regarding the mechanism of action.

Key Concept

Management of acute opioid withdrawal using central alpha-2 adrenergic agonists (e.g., clonidine, lofexidine) when opioid substitution therapy is refused or contraindicated.
Rate this question